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Summary. Background: Factors associated with post-
thrombotic syndrome are known clinically, but the under-
lying cellular processes at the vein wall are not well
delineated. Prior work suggests that vein wall damage does
not correlate with thrombus resolution but rather with
plasminogen activator-1 (PAI-1) and matrix metallopro-
teinase (MMP) activity. Objective: We hypothesized that
PAI-1 would confer post venous thrombosis (VT) vein wall
protection via a vitronectin (Vn)-dependent mechanism.
Methods: A stasis model of VT was used with harvest over
2 weeks, in wild-type, Vn/, and PAI-1–overexpressing
mice (PAI-1 Tg). Results: PAI-1 Tg mice had larger VT at
6 and 14 days, compared to controls, but Vn/ mice had
no alteration of VT resolution. Gene deletion of Vn
resulted in an increase in, rather than the expected decrease
in, circulating PAI-1 activity. While both Vn/ and PAI-1
Tg had attenuated intimal fibrosis, PAI-1 Tg had signifi-
cantly less vein wall collagen and a compensatory increase
in collagen III gene expression. Both Vn/ and PAI-1 Tg
vein wall had less monocyte chemotactic factor-1 and fewer
macrophages (F4/80), with significantly less MMP-2 activ-
ity and decreased TIMP-1 antigen. Ex vivo assessment of
transforming growth factor b–mediated fibrotic response
showed that PAI-1 Tg vein walls had increased profibrotic
gene expression (collagens I and III, MMP-2, and
a–smooth muscle actin) compared with controls, opposite
of the in vivo response. Conclusions: The absence of Vn
increases circulating PAI-1, which positively modulates
vein wall fibrosis in a dose-dependent manner. Translation-
ally, PAI-1 elevation may decrease vein wall damage after
deep vein thrombosis, perhaps by decreasing macrophage-
mediated activities.
Keywords: fibrosis; PAI-1; postthrombotic syndrome;
venous thrombosis; vitronectin.
Introduction
Deep venous thrombosis (DVT) is a significant health care
problem in the United States, with 250 000 to 900 000
patients affected yearly [1,2]. An additional 200 000
patients are affected by the late sequelae of post throm-
botic syndrome (PTS), characterized by leg pain, sensa-
tions of heaviness, limb edema, discoloration, and
occasionally ulceration [3]. The end result after DVT is
the conversion of a compliant, thin-walled vein with func-
tional valves into a thick-walled vessel, often with non-
functioning valves [4]. The physiological result of
damaged veins is pooling of blood in the dependent
extremities, producing venous hypertension and pain, fluid
transudation, edema, and, in severe cases, ulceration.
Despite effective anticoagulant therapy treatments for
DVT, there are no therapies that specifically target the PTS
remodeling processes [5]. While surgical and interventional
therapy may be beneficial for selected patients, treatment
for PTS is mainly supportive, consisting of compression
and wound care. Although compression therapy may pro-
vide symptomatic relief, it does not correct the fundamen-
tal changes that occur in the venous system. Indeed, recent
data from a randomized controlled trial of compression for
preventing PTS did not show a benefit compared with pla-
cebo [6]. An improved understanding of the biology of
PTS, including potential therapeutic targets, is crucial in
the effort to develop effective treatments.
Correspondence: Peter K. Henke, University of Michigan Health
System, 1500 E. Medical Center Drive, Cardiovascular Center, 5463,
Ann Arbor, MI 48109-5867, USA.
Tel.: +1 734 763 0250; fax: +1 734 647 9867.
E-mail: henke@umich.edu
Received 31 March 2014
Manuscript handled by: W. Aird
Final decision: P. H. Reitsma, 12 June 2014
© 2014 International Society on Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis, 12: 1353–1363 DOI: 10.1111/jth.12644
We have recently shown the importance in plasminogen
activator-1 (PAI-1) in post-DVT vein wall remodeling [7].
Gene deletion of PAI-1 hastened venous thrombus resolu-
tion in a mouse model of stasis DVT but resulted in a
thickened and collagen-rich vessel wall. Thrombin-anti-
thrombin levels were not elevated in the thrombi of PAI-
1–null mice, suggesting that the mechanism of increased
fibrosis was not due to PAI-10s thrombin inhibitory activ-
ity but possibly to its role in binding vitronectin (Vn), an
abundant plasma glycoprotein.
Vitronectin is produced by the liver and found circulating
at appreciable levels in the plasma, in the a-granules of
platelets, and in the extracellular matrix [8]. It plays a multi-
faceted role in vascular biology, particularly with regard to
thrombogenesis, pericellular proteolysis, leukocyte recruit-
ment, and cellular adhesion/migration [8,9]. Vn has been
associated with fibrosis of organ systems such as liver [10,11]
and lung [12,13] and implicated as a mediator of neointima
formation in the arterial vasculature [14–16]. To date, its
effect on post thrombotic venous remodeling is unknown.
Experimental models of arterial thrombosis differ with
regard to the role of Vn, with some data suggesting that
it plays a key role in promoting arterial thrombogenesis
[17] and stabilization of thrombi [18], while other data
suggest an inhibitory role in thrombogenesis [19]. How-
ever, little is understood about how or if Vn contributes
to venous thrombosis (VT), with only one study to date
demonstrating increased time to occlusion in Vn/ mice
undergoing photochemically induced thrombosis of the
jugular vein [17]. In this study, we hypothesize that (i) Vn
inhibits thrombus resolution via stabilization of PAI-1
and (ii) Vn contributes to vein wall fibrosis via increased
monocyte vein wall infiltration.
Methods
Animals
Male C57BL/6 (wild-type [WT]) mice (Jackson Labora-
tory, Farmington, CT), Vn gene-deleted (Vn/) mice [20]
(backcrossed > 10 generations on C57BL/6 mice), and
PAI-1–overexpressing mice (PAI-1 Tg, backcrossed > 10
generations on C57BL/6 background) [21] were used in this
study. Initial pilot studies comparing homozygous litter-
mates without transgene (PAI-1 Tg littermates) to C57BL/
6 controls demonstrated identical phenotype with regard to
VT (similar size and cellular morphology). Thus, in the
interest of humane and responsible animal use, C57BL/6
mice were used as controls (rather than homozygous litter-
mates) for all experiments. Animals ranged from 8 to
10 weeks of age with average weight of 24.2 g (WT),
24.4 g (Vn), and 24.6 g (PAI-1 Tg). All work was approved
by the University of Michigan Committee on Use and Care
of Animals and was performed in compliance with the
“Guide for the Care and Use of Laboratory Animals” pub-
lished by the U.S. National Institutes of Health.
Model of DVT
A DVT model of IVC ligation, or stasis thrombosis, was
performed as described previously [22]. Briefly, mice were
anesthetized via 2% inhaled isoflurane. Inferior vena cava
(IVC) exposure was gained via midline laparotomy, and
dorsal branches were interrupted with electrocautery. Side
branches and the infrarenal IVC were ligated with 7-0
Prolene (Ethicon, Inc, Somerville, NJ, USA) to generate
blood stasis and ultimately thrombosis. Fascial closure
was performed with 5-0 Vicryl suture and skin closure
with Vetbond tissue adhesive (3M Animal Care Products,
St. Paul, MN, USA). Mice were euthanized at 2, 6, and
14 days postthrombosis with the collection of plasma,
vein wall, and thrombus. The vein wall and the thrombus
were harvested separately at all time points [22,23]. Before
processing, the IVC and its associated thrombus were
weighed (grams) and measured (centimeters). Thrombus
weight, encompassing the thrombus and the vein wall,
was used as a measure of thrombosis resolution [22,24].
Gelatin zymography of matrix metalloproteinase-2 and -9
Gelatin substrate zymography was performed using pre-
cast 10% sodium dodecylsulfate (SDS)–polyacrylamide
gels containing 1 mg mL gelatin (unless otherwise stated,
all zymographic supplies were from Novex, San Diego,
CA, USA) [25–27]. Vein wall tissue was homogenized in
SDS, centrifuged for 10 min at 2000 9 g. Supernatants
were aliquoted equally and diluted with Tris–glycine–SDS
sample buffer and electrophoretically separated under
non-reducing conditions. Separated proteins were re-nat-
ured in 2.7% Triton X-100 for 2 h to induce gelatin lysis
by re-natured matrix metalloproteinases (MMPs). The gels
were developed for 48 h at 37 °C in 50 mmol L Tris-
HCl, 5 mmol L CaCl2, and 0.2% Brij 35, followed by
staining with Coomassie Blue and destaining in 10% acetic
acid. MMP activity was evident by clear bands against a
darkly stained background where the substrate has been
degraded by the enzyme. Samples containing human
recombinant MMP-2 and MMP-9 (Oncogene, Boston,
MA, USA) were included as standards. Concentrations of
the densitometry analysis were performed using a FOTO/
Analyst CCD CAMERA (Fotodyne, Hartland, WI, USA)
and GEL-Pro Analyzer software version 3.1 (Media
Cybernetics, Silver Springs, MD, USA). Ratios of optical
densities/total protein were calculated. Results were nor-
malized to total protein using a bicinchoninic acid protein
assay kit, assessing colorimetric detection and quantifica-
tion of total protein, which was read between 560 and
590 nm (Pierce, Rockford, IL, USA).
Antigen determination
Antigen determination via enzyme linked immunosor-
bent assay (ELISA) was performed on vein wall
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homogenate for monocyte chemotactic protein 1 (MCP-
1), interleukin (IL)-1b, and IL-13 (R&D Systems, Min-
neapolis, MN, USA). Samples were aliquoted in dupli-
cate on plates precoated with appropriate capture
antibody and then detected by use of a biotinylated
antibody, followed by tetramethylbenzadine substrate
according to the manufacturer’s protocol. The results
were read on an Elx808 plate reader (Biotek, Winooski,
VT, USA) at a 450-nm wavelength. Total protein was
measured by using a bicinchoninic acid protein assay
kit, as detailed in the preceding section. Results were
normalized to total protein (mg).
PAI-1 activity assay
To measure active murine PAI-1 concentrations in plasma
samples, human urokinase plasminogen activator (Abcam,
Cambridge, MA, USA) was coupled to carboxylated beads
(Luminex) and used to capture active PAI-1. A standard
curve was generated using known concentrations of murine
PAI-1 in PAI-1–depleted mouse plasma (Molecular Inno-
vations, Novi, MI, USA). The sample, 10 lL PBS–1%
BSA, and 5000 beads in 30 mL of PBS-1% BSA were incu-
bated overnight at 4 °C. The beads were mixed with biotin-
labeled rabbit anti-mouse PAI-1 (Molecular Innovations)
followed by the addition of streptavidin-R-phycoerythrin
(Molecular Probes). The beads were then read with the
Luminex 100 (median setting, 100 mL sample size, 100
events/bead).
Real-time quantitative polymerase chain reaction (RT-PCR)
Immediately on harvest, vein wall segments were pre-
served in TRIzol reagent. The samples underwent reverse
transcription with the addition of oligo(dT) primer and
dNTP at 65 °C for 5 min followed by first strand buffer,
dithiothreitol, and ribonucleoside inhibitor at 37 °C for
2 min. M-MLV Reverse Transcriptase (Life Technologies,
Carlsbad, CA, USA) was added and RNA heated to
37 °C for 50 min and then 70 °C for 20 min. The resul-
tant cDNA was amplified by Taq polymerase in the Rot-
ogene qPCR system (Qiagen Inc, Valencia, CA, USA).
Rotogene quantification uses the cycle threshold (Ct) for
the gene of interest normalized to the housekeeping gene
b-actin. Relative mRNA expression is calculated by the
formula 2  (Ct target gene  Ct reference gene), and
cycle lengths used are within the exponential phase of the
PCR [28]. These primers included b-actin, procollagen
(Col)1a2, Col3a, MMP-2, and a–smooth muscle actin
(a-SMA).
Histology, immunohistochemistry, and collagen staining
The IVC and associated thrombi were harvested en bloc,
fixed in formalin, embedded in paraffin, and cut into 5-
lm sections as previously described [29,30]. Vein wall
monocyte cell counts were performed following staining
with F4/80 antibody (1:100; Abcam, Cambridge, MA,
USA). Briefly, non-specific binding sites were blocked
with normal serum, and primary antibody was added,
followed by biotin-labeled secondary antibody (rat IgG).
An avidin–biotin–peroxidase complex was performed
according to manufacturer’s instructions (Vector Labora-
tories Inc, Burlingame, CA, USA), and the slides were
counterstained with hematoxylin and eosin. Monocyte
cell counts of five representative high-power fields of
both vein wall and thrombus were performed in a
blinded fashion [31].
Collagen content was quantified with Picrosirius red
stain as previously described [7,32,33]. These sections
were then analyzed in crossed-plane polarized light from
a monochromatic source to assess cross-linked collagen.
Two images for each were obtained using a Zeiss Axio
M1 scope and Zeiss AxioVision software (Carl Zeiss Mi-
croimaging GmbH, G€ottingen, Germany) at 0 and 90
degrees to the plane of polarization, to capture the bire-
fringence of fibers extinguished in one direction. The
images were analyzed blindly using NIH ImageJ software.
The IVC wall was outlined as a region of interest, and
then the image underwent threshold segmentation to dif-
ferentiate collagen from other (primarily cellular and
empty space) components of the vein wall. A vein wall
collagen score was assigned by using the formula [(%
birefringent area) 9 (measured vein wall area)]/(total
specimen area).
To account for non-collagen vein wall changes, inti-
mal thickness and fibrosis scoring assessed from hema-
toxylin and eosin–stained sections were scored by a
board-certified veterinary pathologist in a blinded
manner as previously described [7,22,31]. Briefly, the
scoring system ranges from a score of 0 (no evidence
of fibrosis) to 3 (intima contains numbers fibroblasts
and is irregularly thickened by large amounts of collag-
enous connective tissue). A consistent mid-section
thrombosed IVC segment was used for all histological
analysis [34–36].
Ex vivo methods of vein wall assessment
The IVC was harvested in control mice (WT and PAI-1
Tg), placed in cold Dulbecco phosphate-buffered saline
with 29 penicillin/streptomycin/glutamine (Gibco, Invi-
trogen, Carlsbad, CA, USA), and cleaned by using a
dissecting microscope [24,34,37]. The vein wall was
divided lengthwise and weighed, and each half was fur-
ther divided into three or four pieces. The vein was incu-
bated in Dulbecco modified Eagle medium (Gibco)
containing 5% FCS and 1% penicillin streptomycin gen-
tamycin with or without transforming growth factor
(TGF)-b1 (10 lg mL1, mouse recombinant; R&D Sys-
tems) in a 12-well plate [38]. The tissue culture was incu-
bated for 24 h at 37 °C in 5% carbon dioxide. The wet
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weight of the vein wall was recorded, and the samples
were gently washed in Dulbecco modified Eagle medium,
placed in TRIzol, and frozen at 80 °C for RT-PCR pro-
cessing.
Statistical analyses
All statistical analyses were performed using GraphPad
Prism version 6.01 for Windows (GraphPad Software, San
Diego, CA, USA). The statistical differences between
groups were determined by using an unpaired t-test with
Welch’s correction, one-way ANOVA analysis with Tukey’s
multiple comparison test, or Dunnett’s multiple comparison
test as deemed appropriate. Data are reported as
mean  standard error of the mean (SEM), and differ-
ences are considered significant at a P value of ≤ 0.05.
Animal numbers (n) for experiments were predetermined
based on independent statistical review, protocols, and
numbers needed for significance. For an a = 0.5 and
power of 80%, n = 5 is sufficient for immunological tests
and n = 10 is sufficient for zymography.
Results
Vn/ mice have paradoxically increased circulating PAI-1
activity
Despite the recent commercial availability of Vn/ mice
and subsequent increase in use, no studies have character-
ized levels of circulating active PAI-1 in these animals.
PAI-1 activity as measured in control mice and at three
time points postthrombosis (2, 6, and 14 days) is demon-
strated in Fig. 1. Both total and active PAI-1 levels were
elevated in the Vn/ mice compared to WT mice.
Contrary to expectations, we found active PAI-1 elevated
36-fold compared to WT mice (Fig. 1A) and total circu-
lating PAI-1 to be elevated 10-fold in Vn/ mice
(Fig. 1B). Active PAI-1 remained elevated in the Vn/
mice following thrombosis with significant elevations at
days 6 and 14, with 82-fold and 39-fold increase over
WT, respectively (Fig. 1C), with similar elevations seen of
total PAI-1 (Fig. 1D). To determine whether the results
we found with regard to thrombus resolution and vein
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wall fibrosis were truly due to alterations in PAI-1 activ-
ity in these animals or rather a secondary function of Vn,
we included a comparison cohort of PAI-1 Tg with nor-
mal endogenous Vn. Levels of active circulating PAI-1 in
these animals were markedly elevated at baseline (137-
fold) and postthrombosis (15- to 412-fold) compared to
WT (Fig. 1A, C). Similar elevations were seen in total
PAI-1 at baseline (172-fold) and postthrombosis
compared to WT (10- to 54-fold) (Fig. 1B, D).
Venous thrombogenesis and thrombus resolution are
unaffected by Vn/
Thrombus weights during acute thrombogenesis, as mea-
sured at day 2, were similar between WT and Vn/ mice
(Fig. 2A). Thrombus resolution, as measured by throm-
bus weight at 6 and 14 days postthrombosis (Fig. 2B),
was also unaffected by Vn /. Transgenic PAI-1–overex-
pressing mice exhibited impairment of thrombus resolu-
tion, with increased residual thrombus weight at 6 and
14 days postthrombosis (Fig. 2B). However, thrombogen-
esis (2 days) was not affected in these animals (Fig. 2A).
Vein wall fibrosis is attenuated by excess PAI-1
Vein wall fibrosis, intimal thickness, and collagen content
were assessed at day 14, and collagen gene expression
assessed at days 6 and 14. Vein wall fibrosis was significantly
diminished in mice with elevated PAI-1 (Vn/ mice and
PAI-1 Tg) at day 14 compared to WT (Fig. 3B). Total vein
wall collagen content, as measured by Picrosirius red stain-
ing [7], demonstrated a stepwise reduction with increasing
levels of circulating PAI-1 (Fig. 3A, E, F). Decreases in vein
wall fibrosis at day 14 were accompanied by a paradoxical
increase in procollagen I and IIIa gene expression in Vn/
(3.7- and 2.1-fold) and PAI-1 Tg (5.3- and 4.7-fold) mice
compared to controls (Fig. 3C, D).
PAI-1 inhibits monocyte recruitment and influx
MCP-1 peaks during the early and middle stages of
thrombus resolution, drives monocytes chemotaxis, and is
implicated in clearance of residual thrombus [39–41]. At
these time points (days 2 and 6), MCP-1 levels were sup-
pressed by ≥ 50% in mice with elevated PAI-1 (Vn/
and PAI-Tg), both in the vein wall (Fig. 4A) and in the
thrombus (Fig. 4B). This correlated with diminished vein
wall (Fig. 4C, E–G) and thrombus (Fig. 4D–G) monocyte
influx at day 14 as measured by positively staining F4/80
cells and impaired thrombus resolution (Fig. 2B) in mice
with markedly elevated circulating PAI-1 (PAI-1 Tg).
Vein wall MMP activity is inversely related to PAI-1 activity
The target of PAI-1 inhibition, plasmin, can serve as an
activator of MMP-2 and -9 [42–44]. Furthermore, mono-
cytes represent a source of MMPs in the postthrombotic
vein wall [29], and recruitment is altered in the presence
of excess PAI-1 (Fig. 4C). In mice with PAI-1 (Vn/
and PAI-1 Tg) elevation, total MMP-9 and -2 levels were
diminished in the postthrombotic vein wall (Fig. 5A, B).
Vein wall TIMP-1 antigen did not account for inhibition
of MMPs and was actually decreased at 6 and 14 days in
Vn/ and PAI-1 Tg mice compared to WT (Fig. 5C).
Genetic alterations in Vn and PAI-1 result in altered
inflammatory cytokine milieu
Proinflammatory cytokine IL-1b is upregulated in the
postthrombotic vein wall [41] and augments PAI-1 pro-
duction by endothelial cells [45–47]. We found that in ani-
mals with very high levels of PAI-1, peak vein wall IL-1b
upregulation was attenuated (Fig. 6A). Consistent with
the antifibrotic phenotype of the PAI-1 Tg mice, we
found a reduction of IL-13 in the vein wall at early and
mid time points postthrombosis (Fig. 6B). The Vn/
mice exhibited an intermediate vein wall cytokine profile:
IL-1b levels approximated those of the PAI-1 Tg mice
and IL-13 levels approximated those of the WT.
PAI-1 Tg vein walls are not antifibrotic ex vivo
Given that vein wall fibrosis was reduced in PAI-1 over-
expressing mice, we asked if the altered genotype affected
the fibrotic response ex vivo. We used our organ culture
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model [37] to assess the response to fibrotic mediator
TGF-b (Fig. 7). Consistent with the increases seen in vivo
with increased procollagen I and IIIa gene expression in
response to thrombosis compared to WT (Fig. 3C, D),
the ex vivo cultured vein wall demonstrated an increase in
procollagen gene expression in response to fibrotic stimu-
lation with TGF-b (Fig. 7A, B). Additional proteins asso-
ciated with fibrotic injury, MMP-2 (Fig. 7C) and a-SMA
[37] (Fig. 7D), demonstrated increased relative gene
expression in PAI-1 Tg mice vein wall, suggesting that
the antifibrotic effect of PAI-1 overexpression was not
due to fundamental changes in vein wall gene expression
but rather the antifibrotic effect of circulating PAI-1.
Discussion
Vein wall fibrosis after DVT, clinically manifested as PTS, is
a problem with no known direct therapy. Thus, defining the
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mechanisms of vein wall fibrosis is important translational-
ly. In this study, we have shown the following: (i) contrary
to findings in arterial injury models[17–19], the presence of
Vn does not influence the amplitude of thrombogenesis or
thrombus resolution; (ii) Vn/ mice have increased circu-
lating active and total PAI-1 levels; (iii) elevation of PAI-1 is
protective against vein wall fibrosis and inversely correlates
with vein wall MMP activity; (iv) elevation of PAI-1 is
associated with decreased monocyte infiltrate and altered
cytokine profile; and (v) these effects do not appear to be
due to genotype-specific alterations in the vein wall but
rather to the antifibrotic effect of circulating PAI-1.
A significant role of PAI-1 in vascular thrombosis and
thrombus resolution has been confirmed in both animal
and human studies [48]. Consistent with previous data
suggesting that PAI-1 gene deletion does not affect
venous thrombogenesis, we found here that PAI-1
overexpression failed to affect initial thrombus weight
[49]. However, the role of PAI-1’s ‘cofactor’ Vn remains
understudied, with few animal studies evaluating
thrombotic potential in Vn/ mice and none specifically
evaluating the deep venous system [17–19]. In a small ves-
sel model of photochemically induced VT, thrombogene-
sis was impaired in Vn/ mice [17]. This contrasts to our
data, which demonstrate that in the deep vein system, at
the time of peak thrombogenesis, there was no difference
between thrombus weight and size in Vn/ and WT
mice. The discrepancy between these results suggest that
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body F4/80. T = thrombus. *P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 by analysis of variance with Dunnett’s multiple comparison
test.
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Vn may function very early in thrombogenesis, as the
photochemical model was used to study early thrombus
formation at a very early time point (3–24 h), or that Vn
is less essential to stasis-induced thrombus formation.
Furthermore, Vn deletion does not hasten thrombus reso-
lution, in contrast with PAI-1/ mice [7]. These findings
are supported by elevation of active PAI-1 levels in Vn
/ mice, perhaps due to inability of PAI-1 to remain
localized to site of fibrin formation or extracellular matrix
via its interaction with Vn. Transgenic overexpression of
PAI-1, which produced levels 3 to 17 times higher than
those of the Vn/ mice, resulted in incremental inhibi-
tion of thrombus resolution with larger VT, suggesting
that the effect of PAI-1 on thrombus resolution is likely
dose dependent.
Although genetic deletion of PAI-1 is associated with
increased fibrinolysis by secondary increasing plasmin
activity and smaller VT, an increase in vein wall fibrosis
was observed [7]. PAI-1’s role in organ fibrosis is complex
and dependent on the animal model. For example, diver-
gent results with PAI-1 deletion exist in arterial injury
models, with increased medial hyperplasia after wire
injury [50], or decreased medial hyperplasia after ferric
chloride injury [51]. From the current study, the mecha-
nisms of PAI-1 antifibrotic effect are likely two-fold;
first, significantly decreased MMP-2 and -9 activity in the
postthrombotic vein wall was found. Elevation of both
MMPs is associated with postthrombotic vein wall
fibrosis [37,52,53], and a reduction is consistent with
attenuated fibrotic injury. Second, fewer macrophages
(and consistently decreased MCP-1) were found in the
vein wall and thrombus of PAI-1 Tg and Vn/ mice.
While macrophages may have profibrotic or antifibrotic
activities [54], it is likely in the current experiments that
less profibrotic signaling was present in the PAI-1 Tg
mice. In lung injury models, IL-1b [55] and IL-13 [56] are
profibrotic. Consistently, in the current model, IL-1b and
IL-13 were significantly elevated in WT mice postthrom-
bosis, and reduction of these profibrotic mediators may
also account for the observed reduction in fibrotic injury.
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Binding of PAI-1 to its ‘cofactor’ Vn stabilizes and
confers PAI-1 to a longer half-life, contributing to local
antifibrinolytic activity but also indirectly enhancing the
antiadhesive functions of PAI-1. PAI-1 competes with
monocyte surface receptor urokinase plasminogen activa-
tor receptor for the NH2 terminus of Vn [8]. Binding of
PAI-1 displaces urokinase plasminogen activator receptor
and inhibits monocyte adhesion [57]. Vn also exhibits a
variety of PAI-1–independent activities, including increas-
ing cellular migration [13] and vascular permeability [58].
Interestingly, the vein walls from PAI-1 Tg mice were not
intrinsically resistant to a profibrotic stimulus. Indeed,
using a low TGF-b dose, we found PAI-1 Tg vein walls
were more likely to have increased collagen gene expres-
sion and fibrotic gene markers of MMP-2 and a-SMA.
This suggests that the antifibrotic phenotype associated
with elevated PAI-1 in our model was not the result of
genotype-specific decreased vein wall susceptibility to
fibrosis but more likely the antifibrotic effect of circulat-
ing PAI-1.
Postthrombotic vein wall injury is complex, and new
data suggest that compression therapy may not be truly
effective [59]. New and specific therapies are needed, par-
ticularly since aggressive thrombolysis may be limited to
specific good-risk patients within an early timeframe, and
carries a risk of life-threatening hemorrhage [60]. In this
study, we demonstrated that increased circulating PAI-1,
either from gene deletion of PAI-1 ligand Vn or in setting
of transgenic overexpression, is associated with attenuated
fibrosis of the postthrombotic vein wall. While it is unli-
kely that exogenous PAI-1 would be practical as it would
impair thrombus resolution, interruption of PAI-1–fibrin
interaction via specific targeting of vitronectin [61] has
the potential to decrease vein wall fibrotic response with-
out affecting thrombus resolution and represents a future
area of study.
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